ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
EU Marketing Authorisation change for Maviret
March 10, 2020The European Commission has granted AbbVie permission to change the Marketing Authorisation for Maviret (glecaprevir/pibrentasvir) to eight weeks of treatment. -
European Commission Grants AbbVie Marketing Authorization for Shorter MAVIRET Treatment
March 09, 2020AbbVie announced that the European Commission has approved a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration ... -
Cure Hepatitis C in 8 Weeks: Maviret, the Hepatitis C Drug with the Best Efficacy in the World, has Entered China
June 04, 2019The National Medical Products Administration of China (NMPA) has approved the marketing of AbbVie’s direct-acting antiviral (DAA) Maviret (glecaprevir/pibrentasvir) on May 15, 2019.
Pharma Sources Insight January 2025
